GMP Cell Therapy Consumables Global Market Report 2024

The gmp cell therapy consumables market size has grown exponentially in recent years. It will grow from $14.13 billion in 2023 to $18.25 billion in 2024 at a compound annual growth rate (CAGR) of 29.2%. The growth witnessed in the historical period can be ascribed to increased investments in regenerative medicine, progress in cell therapy research, approvals and clinical trials, a rise in the prevalence of chronic diseases, and heightened awareness of personalized medicine.

The gmp cell therapy consumables market size is expected to see exponential growth in the next few years. It will grow to $46.86 billion in 2028 at a compound annual growth rate (CAGR) of 26.6%. The anticipated growth in the forecast period can be linked to the broadening applications of cell therapy, a worldwide surge in cell therapy trials, regulatory backing for cell therapies, the advent of advanced cell therapy platforms, and the global expansion of cell therapy manufacturing. Prominent trends expected in the forecast period encompass investments in manufacturing infrastructure, technological advancements in cell processing, collaborative efforts and partnerships, digitalization and data integration, as well as strategic alliances and mergers.

The growth of the GMP cell therapy consumables market is anticipated to be propelled by the increasing focus on drug discovery. Drug discovery involves the identification of potential new medicinal entities through the integration of computational, experimental, translational, and clinical models. Technological advancements in molecular biology, genetics, bioinformatics, and high-throughput screening have significantly enhanced the drug discovery process. These advancements empower scientists to gain a better understanding of disease mechanisms, identify potential drug targets, and efficiently screen large compound libraries for potential drug candidates. Notably, the Food and Drug Administration (FDA) reported the approval of 37 new drugs and therapeutic biological products by its Center for Drug Evaluation and Research (CDER) in the US in 2022 for various indications, highlighting the surge in drug discovery and its impact on the GMP cell therapy consumables market.

The increasing prevalence of chronic diseases is expected to drive the growth of the GMP cell therapy consumables market. Chronic diseases, characterized by lasting three months or more and potentially worsening over time, have led to intensified research and development efforts in innovative cell therapies to address these persistent conditions. The expansion of cell therapy applications across various chronic diseases has resulted in a heightened demand for GMP consumables to ensure the quality of clinical trials. Stringent regulatory compliance and the growing demand for innovative therapies, driven by the rising number of individuals with chronic diseases (projected to reach 142.66 million worldwide by 2050 according to the National Center for Biotechnology Information), further contribute to the market's growth. In summary, the increasing prevalence of chronic diseases is a significant driver of the GMP cell therapy consumables market.

Product innovations stand out as a prominent trend gaining traction in the GMP cell therapy consumables market. Companies within the GMP cell therapy consumables sector are actively embracing novel technologies to maintain their market positions. For example, in March 2021, Thermo Fischer Scientific, a US-based supplier of scientific instrumentation, reagents, consumables, and software services, introduced the HyPerforma DynaDrive single-use bioreactors, available in 3,000 and 5,000 L capacities. This innovative system boasts an enhanced turn-down ratio, improved mixing capabilities, and increased scalability. Thermo Fischer Scientific asserts that the solution contributes to a reduced vessel footprint and employs technology optimized for perfusion cell culture operations, effectively conserving manufacturing suite space.

Major companies in the GMP cell therapy consumables market are also concentrating on the development of cutting-edge products, such as cell isolation systems, to gain a competitive advantage. A cell isolation system is a technological platform or device designed to separate specific cells from a mixture based on criteria such as size, markers, or other characteristics. In January 2022, Sony Group Corporation, a Japan-based conglomerate, launched the CGX10 Cell Isolation System, featuring high-speed, high-purity cell sorting within a closed system. The closed structure ensures sterility, making it particularly suitable for applications such as cell-based immunotherapy, where maintaining a sterile environment is crucial. The system, equipped with up to ten parameters and four lasers, enables the isolation of cells with approximately 97% purity at a speed of 15,000 cells per second. The use of a single-use disposable tubing kit minimizes the risk of cross-contamination between samples, showcasing Sony's commitment to advancing cell therapy development and manufacturing.

In September 2022, Cellistic, a Belgium-based company specializing in cell therapies based on human induced pluripotent stem cell (iPSC) technology, acquired Celyad Oncology's GMP-grade cell therapy manufacturing facility for $7.46 million. This strategic acquisition positions Cellistic to leverage the acquired skills and assets, advancing the development of its unique platforms and enhancing the capacity to assist partners in delivering iPSC-based allogeneic cell therapies to patients more efficiently. Celyad Oncology, a renowned biotechnology firm based in Belgium, is dedicated to exploring and developing innovative chimeric antigen receptor (CAR) T-cell therapies designed specifically to combat cancer.

Major companies operating in the gmp cell therapy consumables market report are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Danaher Corporation, Merck KGaA, Asahi Kasei Corporation, GE HealthCare Technologies Inc., Corning Incorporated, Avantor Inc., Lonza Group AG, Terumo Corporation, Catalent Inc., Sartorius AG, Bio-Techne Corp, Repligen Corporation, Miltenyi Biotec BV & Co KG, Genscript Biotech Corporation, Rentschler Biopharma SE, FUJIFILM Irvine Scientific Inc., BioLegend Inc., STEMCELL Technologies Inc., BioLife Solutions Inc., Abzena Ltd., Sino Biological Inc., ProBioGen AG, MaxCyte Inc., PromoCell GmbH, PeproTech Inc., Cellares Corp., Wilson Wolf Corporation, Cellexus Ltd.

North America was the largest region in the GMP cell therapy consumables market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gmp cell therapy consumables market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gmp cell therapy consumables market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of GMP cell therapy consumables include kits, reagents or molecular biology reagents, growth factors or cytokines and interleukins, and other essential components. A kit is a compilation of items, such as tools or equipment, intended for a specific activity or purpose. In the realm of GMP cell therapy consumables, kits are utilized for tasks such as the isolation, expansion, harvesting, and formulation of cell therapies. These therapies encompass NK cell therapy, stem cell therapy, T-cell therapy, and others, involving processes such as cell collection and characterization or sorting and separation, cell culture and expansion or preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution or handling, process monitoring and control or re-administration or quality assurance, among others. GMP cell therapy consumables find application in clinical, commercial, and research settings.

The GMP cell therapy consumables market research report is one of a series of new reports that provides GMP cell therapy consumables market statistics, including the GMP cell therapy consumables industry's global market size, regional shares, competitors with a GMP cell therapy consumables market share, detailed GMP cell therapy consumables market segments, market trends, and opportunities, and any further data you may need to thrive in the GMP cell therapy consumables industry. This GMP cell therapy consumables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The GMP cell therapy consumables market consists of sales of cell culture media, media supplements, extracellular matrices, flasks, tubes, dishes or cryovials, serological pipettes, or centrifugation tubes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.